- Intraprostatic injection of botulinum toxin-A (Botox; BTX‐A) significantly improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Why this matters
- Intraprostatic BTX‐A injection is a minimally invasive, nonsurgical BPH treatment alternative.
- Researchers studied patients with LUTS secondary to BPH who were treated with BTX-A injection after failing previous medical treatment or refusing surgical intervention (n=45; mean age, 64.4±6.6 years).
- They measured relevant clinical characteristics at baseline and at 2, 4, 8, and 12 weeks after injection.
- Funding: None disclosed.
- Mean international prostate symptom score (IPSS) decreased from 24.06 to 18.75 at 2 weeks and reached 16.37 at 12 weeks (P<.001>
- Mean maximum urinary flow rate (Qmax) increased from 9.08 to 10.44 mL/s at 2 weeks and 11.44 mL/s at 12 weeks (P<.001>
- Mean postvoiding residual urine (PVR) decreased from 82.62 to 57.66 mL at 12 weeks (P<.001>
- Mean prostate volume decreased from 67.44 to 66.06 cc at 12 weeks (P<.001>
- Patients reported no significant complications requiring medical treatment.
- The study had a small sample size and no placebo control group.